Review in Molecular Biology Reports analyzes senolytic and senomorphic strategies in tumor immune microenvironments

A peer-reviewed review in Molecular Biology Reports outlines the potential of combining senogenic, senolytic, and senomorphic therapies to turn therapy-induced cellular senescence from an immunosuppressive liability into a therapeutic opportunity in oncology.

A review paper published in Molecular Biology Reports details the molecular regulation of the senescence-associated secretory phenotype (SASP) and its influence on the tumor immune microenvironment (TIME).

The authors describe therapy-induced senescence (TIS) as a non-lethal, metabolically active outcome of chemotherapy, radiotherapy, and targeted treatments.

The paper emphasizes the biphasic nature of SASP, which promotes immune surveillance when transient but drives chronic inflammation, immune evasion, and recurrence when senescent cells persist.

The review proposes sequential combination strategies involving senogenic agents (to induce senescence) followed by senolytics (to selectively clear senescent cells) or senomorphics (to suppress harmful SASP elements).

Therapy-induced senescence has historically acted as a double-edged sword, where the lingering presence of senescent cancer and stromal cells can foster treatment resistance and tumor relapse.

Developing systematic regimens that first induce and then target senescent cells represents a shift toward exploiting cellular senescence therapeutically in oncology rather than treating it merely as a side effect.

The clinical translation of this approach faces significant hurdles, including the need for higher biomarker specificity, managing cell-type heterogeneity, optimizing dosing schedules, and utilizing spatial monitoring.

The review supports the expansion of senolytic and senomorphic applications beyond age-related degenerative indications, indicating a broader oncology-related market for platforms clearing or modulating senescent cells.

Biotechnology firms focusing on cellular senescence clearance may find new avenues for therapeutic validation and strategic oncology partnerships.

However, the complex translational barriers detailed in the paper suggest that commercial clinical validation in oncology remains long-term and technically challenging.

Preclinical and early-stage clinical trials evaluating the safety, timing, and efficacy of sequential senogenic-senolytic regimens, particularly when paired with immune checkpoint inhibitors.

The development of high-resolution spatial transcriptomics and in vivo imaging techniques to monitor senescent niches within the tumor immune microenvironment.